Skip to Main content Skip to Navigation
New interface
Journal articles

Kill ‘Em All: Efgartigimod Immunotherapy for Autoimmune Diseases

Jagadeesh Bayry 1 Srini V. Kaveri 1 
1 CRC - Inserm U1138 - Immunopathologie et immunointervention thérapeutique
CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
Abstract : Neonatal Fc receptors (FcRns) recycle IgGs by preventing their lysosome degradation. As this process also enhances half-life of pathogenic auto-IgG, inspired from the mechanisms of intravenous immunoglobulin, several inhibitors of IgG-FcRn interface have been conceived for treating autoimmune diseases. Among them, the high-affinity FcRn-binding engineered Fc molecule efgartigimod has recently completed phase I clinical trial.
Complete list of metadata
Contributor : Jagadeesh Bayry Connect in order to contact the contributor
Submitted on : Sunday, January 26, 2020 - 10:56:56 AM
Last modification on : Wednesday, September 28, 2022 - 4:20:11 PM



Jagadeesh Bayry, Srini V. Kaveri. Kill ‘Em All: Efgartigimod Immunotherapy for Autoimmune Diseases. Trends in Pharmacological Sciences, 2018, 39 (11), pp.919-922. ⟨10.1016/⟩. ⟨inserm-02455435⟩



Record views